The role of prednisolone in preventing intestinal complications in patients of Abdominal TB

Double blind, parallel arm randomized controlled trial for preventing intestinal complications by concomitant prednisolone with standard anti-tuberculosis regimen in patients of abdominal tuberculosis - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104006

Enrollment

100

Registered

2026-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A183- Tuberculosis of intestines, peritoneum and mesenteric glands

Interventions

Intervention1: ATT plus Steroid: Standard anti-tubercular drug regimen (per the National TB Elimination Programme guidelines for abdominal TB) for 6-9 months plus oral Prednisolone for 3 months. Contr

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either gender and Age more than 14 years Newly diagnosed and treatment na ve patients of abdominal tuberculosis Willing and able to provide written informed consent Able to comply with the study protocol and follow-up schedule

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Proportion of patients in each arm who develop at least one of the following within 12 months of initiating treatment: Intestinal stricture, Intestinal obstruction, Need for abdominal surgery. Timepoint: 12 months	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactNitish Sharma

Jawaharlal nehru medical college and hospital, AMU

hadyman2k@gmail.com8958786889

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026